- Trials with a EudraCT protocol (115)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
115 result(s) found for: Endometrial polyps.
Displaying page 1 of 6.
| EudraCT Number: 2014-000991-25 | Sponsor Protocol Number: Metform03 | Start Date*: 2014-09-23 | |||||||||||
| Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust | |||||||||||||
| Full Title: Pre-surgical metformin for women with endometrial cancer: a randomised placebo controlled trial | |||||||||||||
| Medical condition: Endometrial carcinoma or hyperplasia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-001447-40 | Sponsor Protocol Number: 28UCS2019 | Start Date*: 2020-06-29 | ||||||||||||||||
| Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA | ||||||||||||||||||
| Full Title: Pilot Study of Daily Exemestane in Women with Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer | ||||||||||||||||||
| Medical condition: Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer in post-menopausal women | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2022-001237-37 | Sponsor Protocol Number: NL81058.041.22 | Start Date*: 2022-09-22 | ||||||||||||||||||||||||||
| Sponsor Name:University Medical Center Utrecht | ||||||||||||||||||||||||||||
| Full Title: SENtinel lymph node mapping with GAllium-68-tilmanocept PET/CT in high/high-intermediate risk endometrial cancer: a pilot study | ||||||||||||||||||||||||||||
| Medical condition: The IMP will be used for the identification of sentinel lymph nodes in patients with high/high-intermediate risk endometrial cancer. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||
| Trial protocol: NL (Trial now transitioned) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2014-001434-29 | Sponsor Protocol Number: VX-EC-2-2013 | Start Date*: 2015-01-13 | |||||||||||||||||||||
| Sponsor Name:AS Kevelt | |||||||||||||||||||||||
| Full Title: A Phase II Study of Sodium Cridanimod in Conjunction with Progestin Therapy in Patients with Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma. | |||||||||||||||||||||||
| Medical condition: PrR negative papillary serous adenocarcinoma, endometroid type of endometrial carcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
| Trial protocol: CZ (Completed) SK (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2011-001382-40 | Sponsor Protocol Number: Metform01 | Start Date*: 2011-09-09 | |||||||||||
| Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust | |||||||||||||
| Full Title: Proof of mechanism pre-surgical window trial of metformin in non-diabetic women with endometrial carcinoma: a feasibility study | |||||||||||||
| Medical condition: Endometrial carcinoma or hyperplasia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-002443-21 | Sponsor Protocol Number: CO44195 | Start Date*: 2023-03-01 | ||||||||||||||||
| Sponsor Name:F. HOFFMANN - LA ROCHE LTD. | ||||||||||||||||||
| Full Title: A PHASE II, SINGLE-ARM STUDY OF GIREDESTRANT IN PATIENTS WITH GRADE 1 ENDOMETRIAL CANCER | ||||||||||||||||||
| Medical condition: Grade 1 Endometrial Cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2015-001732-38 | Sponsor Protocol Number: 1502 | Start Date*: 2015-09-14 | |||||||||||
| Sponsor Name:CENTRE OSCAR LAMBRET | |||||||||||||
| Full Title: EVALUATION OF SENTINEL NODE (SN) POLICY IN EARLY STAGE ENDOMETRIAL CARCINOMAS AT INTERMEDIATE AND HIGH RISK OF RECURRENCE: RANDOMIZED STUDY COMPARING SENTINEL NODE POLICY TO CURRENT FRENCH INITIAL ... | |||||||||||||
| Medical condition: Intermediate-risk endometrioïd carcinomas : IAg3, IB(II)g1-2 High-risk endometrioïd carcinomas : IB-II g3 High-risk non endometrioïd carcinomas : I-II | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-000193-38 | Sponsor Protocol Number: ENGOT-EN1/FANDANGO | Start Date*: 2016-06-20 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Nordic Society of Gynaecological Oncology (NSGO) - CTU | ||||||||||||||||||||||||||||||||||||||
| Full Title: ENGOT-EN1/FANDANGO: A randomized phase II trial of first-line combination chemotherapy with nintedanib / placebo for patients with advanced or recurrent endometrial cancer. | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Histological confirmed endometrial cancer. (FIGO 2009) stage 3C2 or stage 4 or relapsed after adjuvant therapy for stage 1-3 disease. | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: SE (Completed) DK (Prematurely Ended) DE (Completed) FI (Completed) BE (Completed) FR (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2009-010613-68 | Sponsor Protocol Number: X-55-58064-004 | Start Date*: 2009-07-06 | |||||||||||
| Sponsor Name:Ipsen Pharma | |||||||||||||
| Full Title: A phase II international multicentre randomised open label study of oral steroid sulphatase inhibitor BN83495 versus megestrol acetate (MA) in women with advanced or recurrent endometrial cancer | |||||||||||||
| Medical condition: Advanced or recurrent endometrial cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: BE (Completed) GB (Completed) FR (Completed) ES (Prematurely Ended) CZ (Completed) HU (Completed) PL (Completed) LT (Completed) LV (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-000299-33 | Sponsor Protocol Number: AGO-GYN8 | Start Date*: Information not available in EudraCT | ||||||||||||||||
| Sponsor Name:AGO Research GmbH | ||||||||||||||||||
| Full Title: Efficacy, tolerability and safety of Temsirolimus in women with platinum-refractory ovarian carcinoma or advanced endometrial carcinoma | ||||||||||||||||||
| Medical condition: platinum-refractory ovarian carcinoma or advanced endometrial carcinoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2013-003469-32 | Sponsor Protocol Number: UCL/13/0045 | Start Date*: 2014-10-13 | |||||||||||
| Sponsor Name:University College London | |||||||||||||
| Full Title: A Single Arm Phase II trial of BMN 673 for inoperable, advanced endometrial cancer with retrospective PTEN, MSI and MRE11 analysis. | |||||||||||||
| Medical condition: Inoperable, advanced, recurrent or metastatic endometrial cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-000843-14 | Sponsor Protocol Number: GEICO_70-E | Start Date*: 2018-06-27 | |||||||||||||||||||||
| Sponsor Name:GEICO (Grupo Español de Investigación en Cáncer de Ovario) | |||||||||||||||||||||||
| Full Title: A phase II multicenter, open-label, single arm trial of avelumab in combination with pegylated liposomal doxorubicin in recurrent/metastatic endometrial cancer | |||||||||||||||||||||||
| Medical condition: recurrent/metastatic endometrial cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2019-004112-60 | Sponsor Protocol Number: D9311C00001 | Start Date*: 2020-06-16 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or with... | |||||||||||||
| Medical condition: Endometrial Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: BE (Trial now transitioned) GR (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) LT (Trial now transitioned) ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-001848-20 | Sponsor Protocol Number: ENGOT-EN3-NSGO/PALEO | Start Date*: 2016-09-28 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Nordic Society of Gynaecological Oncology - Clinical Trial Unit (NSGO-CTU) | ||||||||||||||||||||||||||||||||||||||
| Full Title: A randomized, double-blind, placebo-controlled, phase II trial of Palbociclib in combination with Letrozole versus Placebo in combination with Letrozole for patients with Estrogen Receptor Positive... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Histological confirmed endometrial cancer of endometrioid type. Mixed tumor histology is allowed if the non-endometrioid component is less than 5%. Tumour must be estrogen receptor positive. | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: DK (Completed) FI (Completed) DE (Completed) ES (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2015-000612-17 | Sponsor Protocol Number: HyperplasiLNG | Start Date*: Information not available in EudraCT |
| Sponsor Name:University Hospital of North Norway | ||
| Full Title: Significance of intrauterine progestogen therapy in endometrial proliferative conditions | ||
| Medical condition: Endometrial cancer has presently become the most frequent gynaecologic malinancy in the Western World and the incidence is still increasing. In Norway a 50% increase in occurence has been observed ... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: NO (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-001352-21 | Sponsor Protocol Number: ABT-C5-2016 | Start Date*: 2016-09-19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Ability Pharmaceuticals, SL | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A phase I/ II, open label study to assess the efficacy and safety of ABTL0812 in combination with paclitaxel and carboplatin in patients with advanced endometrial cancer or squamous NSCLC | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Squamous Cell Non-Small Cell Lung Cancer and advanced endometrial cancer | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2009-016858-41 | Sponsor Protocol Number: E7080-G000-204 | Start Date*: 2010-10-05 | ||||||||||||||||||||||||||
| Sponsor Name:Eisai Ltd. | ||||||||||||||||||||||||||||
| Full Title: An Open-Label, Single-Arm, Multicenter Phase 2 Study of E7080 in Subjects with Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy | ||||||||||||||||||||||||||||
| Medical condition: Unresectable endometrial cancer and disease progression following platinum-based, first-line chemotherapy | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||
| Trial protocol: HU (Completed) BG (Completed) BE (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2008-000634-53 | Sponsor Protocol Number: AP23573-07-205(8669-007) | Start Date*: 2008-11-07 | ||||||||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., | ||||||||||||||||||
| Full Title: A randomized phase II trial of ridaforolimus (AP23573; MK-8669) compared to progestin or chemotherapy in female adult patients with advanced endometrial carcinoma | ||||||||||||||||||
| Medical condition: advanced endometrial carcinoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: GB (Completed) DE (Prematurely Ended) CZ (Completed) ES (Completed) IT (Completed) FR (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2012-005546-38 | Sponsor Protocol Number: AEZS-108-050 | Start Date*: 2013-10-14 | ||||||||||||||||
| Sponsor Name:Aeterna Zentaris GmbH | ||||||||||||||||||
| Full Title: Randomised controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer | ||||||||||||||||||
| Medical condition: Endometrial cancer, advanced, recurrent or metastatic | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: CZ (Completed) BE (Completed) GB (Completed) AT (Completed) DE (Completed) ES (Completed) IE (Completed) IT (Completed) BG (Completed) NL (Completed) PL (Completed) DK (Completed) FI (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2008-007167-16 | Sponsor Protocol Number: CA163-196 | Start Date*: 2009-09-29 | ||||||||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
| Full Title: A Phase III Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women with Advanced Endometrial Cancer Who H... | ||||||||||||||||||
| Medical condition: Advanced, recurrent or metastatic endometrial carcinoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: GB (Completed) BE (Completed) IT (Prematurely Ended) ES (Temporarily Halted) FR (Completed) SE (Completed) GR (Completed) DK (Completed) HU (Completed) FI (Completed) CZ (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
